What STERIS does

STERIS plc (NYSE: STE) is a publicly traded infection-prevention, contamination-control, and sterilization company incorporated in Ireland (registered No. 595593) with its U.S. headquarters in Mentor, Ohio. Founded in 1987 and listed since 1992, STERIS reorganized from STERIS Corporation (Ohio) to STERIS plc (Ireland) in November 2015 via a one-for-one share conversion. The company operates three reporting segments: Healthcare (infection prevention products, surgical support systems, consumables, and services for hospitals and medical device manufacturers), Applied Sterilization Technologies (contract sterilization and microbial reduction services using ethylene oxide and other modalities for medical devices and pharmaceuticals), and Life Sciences (capital equipment, consumables, and services supporting contamination control and sterilization in pharmaceutical manufacturing and laboratory research).

Underlying technology is built around proprietary formulated chemistries (high-performance disinfectants, sterilants, and cleaning solutions) and applied sterilization processes — both protected by domain know-how, regulatory certifications, and validated customer integrations. Manufacturing is distributed across the United States, Canada, Germany, and Finland, and the company is constructing a $600 million Formulated Chemistries Center of Excellence in North Carolina, the largest single-site investment in its history.

STERIS generates revenue through an enterprise B2B model combining capital equipment sales, recurring consumable chemistries, and service contracts, sold via a direct global field-sales force (over 1,700 sales, service, and field-support personnel historically) under quote-based pricing. In Q1 FY2027 the company reported $1.5 billion in revenue (7% growth), and FY2026 revenue from continuing operations was $5.2 billion (+9%). The company has delivered 21 consecutive years of dividend growth, guided to approximately $800 million of FY2027 free cash flow, and authorized a $1 billion share repurchase program.

Name

STERIS

Legal name

STERIS plc

Website

https://steris-ir.com

Company type

Public

Founded year

1987

Operating status

Operating

Short description

STERIS plc is a publicly traded global provider of infection prevention, sterilization, and contamination control products and services for hospitals, medical device manufacturers, pharmaceutical companies, and life science research institutions, operating through Healthcare, Applied Sterilization Technologies, and Life Sciences segments.

Ownership category

akta.pro rank

Product category

Infection Prevention and Sterilization

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Soap and Cleaning Compound Manufacturing (32561)

SIC

Surgical & Medical Instruments & Apparatus (3841), Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840)

akta.pro primary industry

Sterilization Services & Contract Reprocessing (ETO/Gamma/E-beam providers) (HLAHANAB)

akta.pro secondary industries

Sterilization Equipment & Systems (Autoclaves, Low-Temp, ETO, H2O2, UV) (HLAHANAA), Radiation Processing & Sterilization Services (Medical device sterilization, food irradiation, materials modification) (EUAKAIAG), Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers) (IMALAIAB)

Keywords

• Infection prevention products
• Sterilization services
• Contamination control
• Healthcare sterilization
• Life sciences equipment

Headquarters

HQ city

Dublin

HQ country

Ireland

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Healthcare Products and Services: Revenue from healthcare segment including capital equipment, consumables, and services. Q1 FY2027 Healthcare revenue grew 8% to $1.05 billion, with 10% service revenue improvement, 9% consumable growth, and 1% capital equipment increase.
2. Applied Sterilization Technologies: Sterilization services segment. Q1 FY2027 revenue increased 6% as reported to $297.6 million, driven by 6% service revenue growth partially offset by 13% decline in capital equipment revenue.
3. Life Sciences: Products and services for pharmaceutical and life science research. Q1 FY2027 revenue increased 9% to $146.7 million with 17% capital equipment growth, 8% consumable improvement, and 2% service growth.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

STERIS manufactures and sells infection prevention products, sterilization capital equipment, consumable chemistries (disinfectants and sterilants), and surgical support systems for healthcare facilities, medical device manufacturers, pharmaceutical manufacturers, and life sciences research organizations. The company also operates contract sterilization and microbial reduction services using ethylene oxide (EO) for medical device and pharmaceutical customers through its Applied Sterilization Technologies (AST) segment.

Product overview

STERIS is a diversified healthcare and life sciences company operating across three core segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment provides infection prevention products, surgical support systems, consumables, and services. The AST segment offers contract sterilization and microbial reduction services. The Life Sciences segment serves pharmaceutical and laboratory applications with contamination control products. The company also manufactures formulated chemistries for infection prevention and has acquired specialized brands including Hausted (patient positioning systems), Royal Sterilization Systems, and Detach AB. STERIS operates globally with manufacturing in the U.S., Canada, Germany, and Finland.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare Segment Products and Services
• Applied Sterilization Technologies (AST)
• Life Sciences Segment Products and Services
• Formulated Chemistries
• Hausted Patient Positioning Systems
• Royal Sterilization Systems Services

Quantifiable outcome

• Q1 FY2027: Revenue increased 7% to $1.5 billion; constant currency organic revenue growth was 6%
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators13 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Sotera Health: Sotera Health operates the Sterigenics, Nelson Labs, and Labstat businesses providing contract sterilization (EO, gamma), lab testing, and advisory services to medical device and pharmaceutical manufacturers — a near-direct competitor to STERIS's Applied Sterilization Technologies segment.
• Getinge: Getinge provides sterilization equipment, infection control solutions, and surgical workflow products to hospitals and life science customers globally, directly overlapping STERIS's Healthcare and sterilization equipment offerings.
• Stericycle: Stericycle provides regulated waste management and reusable sharps and instrument sterilization services to hospitals and healthcare facilities, overlapping with STERIS's healthcare services and infection prevention footprint.
• Advanced Sterilization Products (ASP, a Fortive company): ASP is a leading manufacturer of sterilization and disinfection products, including STERRAD low-temperature hydrogen peroxide systems and endoscope reprocessors, directly competing with STERIS's sterilization equipment and endoscope reprocessing portfolio.
• Belimed (Metall Zug Group): Belimed designs and manufactures steam sterilizers, low-temperature sterilizers, and washer-disinfectors for hospitals and life science labs, competing directly with STERIS's sterilization equipment business.

Broad incumbents

• Ecolab: Ecolab is a large diversified provider of water, hygiene, and infection prevention solutions across healthcare, food service, and industrial markets, overlapping with STERIS's formulated chemistries and healthcare cleaning portfolios at a much broader scale.
• Danaher: Danaher operates a diversified life sciences and diagnostics platform including Cytiva and Pall, overlapping with STERIS's Life Sciences segment through bioprocessing, contamination control, and lab product adjacencies at much greater scale.

Emerging players

• Tuttnauer: Tuttnauer manufactures autoclaves, sterilizers, and laboratory equipment for healthcare, dental, and life science customers, partially overlapping with STERIS's sterilization equipment portfolio, particularly in mid-market and international segments.
• Bio-Rad Laboratories: Bio-Rad provides life science research and clinical diagnostics products, with overlap in lab consumables and contamination control tools that compete with parts of STERIS's Life Sciences offering.
• Miele Professional: Miele Professional supplies industrial washer-disinfectors, sterilizers, and lab cleaning equipment to hospitals, pharmaceutical manufacturers, and laboratories, partially overlapping with STERIS's reprocessing and sterilization equipment portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STERIS